Innovative cancer med-tech, leveraging genomic, histological and clinico-demographic data to predict patient’s responses to cancer immunotherapy.

Min Investment
HORNCHURCH, United Kingdom

Company Description

Curenetics aims to optimise cancer treatment delivery by improving the prediction of immunotherapy treatment response, toxicity, and resistance through data-driven approaches. Our goal is to leverage clinical, genomic and histological biomarker data to develop predictive models of response to immunotherapy for cancers even before commencing treatment. We are backed by several clinical partners and advisors who work alongside us to provide us guidance and support to ensure our product has a good market fit. Our core team is made up of our CEO, CTO/data scientist, COO/AI engineer Operational and Clinical Lead and Immunologist who are working tirelessly to turn our mission into a reality
Amount Raised : £110,000
Reveal the Score by Voting
Additional ratings from other users are needed to determine a viable CrowdScore for this deal.
The "CrowdScore" for this deal is determined by user ratings and other factors using our proprietary algorithm.
The overall viability and scalability of the business concept as well as the ability to drive the concept to profitability over time.
Business Idea
The progress made thus far in demonstrating that the business has viability, a customer base or other business traction.
Business Traction
The experience of the management team in running, scaling and/or exiting a business that required similar skills to execute the business plan.
Management Team
The value of the company compared to similar companies raising money from investors.

Research Reports

No reports have been submitted

Become a Reporter